Who Paid My Doc
Jason Zommick
Las Vegas, NV Medical Doctor
NPI 1255367553 CMS profile 238587
5701 W. Charleston Blvd, Suite 201, Las Vegas, NV 89146
General payments
$12,363
Research payments
$406
Ownership & investment interest
$0
Research they led as principal investigator
$19,859
Through program year 2025, Jason Zommick of Las Vegas, NV is reported in the CMS Open Payments database as having received $12,363 across 106 general payments and $406 in research payments paid to them. Separately, studies naming them as principal investigator received $19,859 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
By program year
8 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $267 | 8 | |
| 2024 | General | $268 | 4 | |
| 2023 | General | $305 | 7 | |
| 2022 | General | $256 | 5 | |
| 2021 | General | $6,218 | 24 | |
| 2020 | General | $4,258 | 19 | |
| 2019 | General | $791 | 39 | |
| 2019 | Research | $406 | 4 |
Beside peers
- Jason Zommick
- Nevada median
- Middle half of Nevada
- National median
In program year 2025, general payments to Jason Zommick were reported at $267. Among 8,799 Nevada profiles paid that year, the median was $206 and the middle half received between $66 and $705.
Show as a table
| Year | Jason Zommick | Nevada median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $791 | $204 | $61–$837 | $163 |
| 2020 | $4,258 | $130 | $40–$438 | $114 |
| 2021 | $6,218 | $175 | $50–$617 | $132 |
| 2022 | $256 | $173 | $52–$609 | $149 |
| 2023 | $305 | $194 | $66–$644 | $160 |
| 2024 | $268 | $196 | $61–$687 | $164 |
| 2025 | $267 | $206 | $66–$705 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 21 drugsPart D claims
2,138
Drug cost
$55,118
Branded share of claims
38.4%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Myrbetriq Mirabegron | Brand | 50 | $28,200 | |
| Tamsulosin Hcl | Generic | 689 | $7,590 | |
| Nitrofurantoin Mono-Macro Nitrofurantoin Monohyd/M-Cryst | Brand | 334 | $2,973 | |
| Oxybutynin Chloride | Generic | 173 | $2,713 | |
| Alfuzosin Hcl Er Alfuzosin Hcl | Brand | 103 | $2,368 | |
| Finasteride | Generic | 169 | $1,814 | |
| Dutasteride | Generic | 20 | $1,573 | |
| Solifenacin Succinate | Generic | 39 | $1,109 | |
| Methenamine Hippurate | Generic | 12 | $1,095 | |
| Oxybutynin Chloride Er Oxybutynin Chloride | Brand | 58 | $1,019 |
The 10 drugs with the highest cost, of 21 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,221 Part D prescribers listed as Urology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 79 billing codesPaid by Medicare
$220,989
Medicare patients
974
Services billed
5,794
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Arthritis | 45% | |
| Ischemic heart disease | 40% | |
| Diabetes | 35% | |
| Chronic kidney disease | 31% | |
| Cancer | 23% | |
| Atrial fibrillation | 21% | |
| Heart failure | 14% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Bcg live intravesical instillation, 1 mg J9030 | Office | 14 | 2,350 | $5,132 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
110 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Related records
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.